We noticed a small portion of regulator genes positively related to majority of compounds, such as NUDT16 (related to 30 cancer drugs in GDSC, 21 in CTRP), METTL1 (related to 30 cancer drugs in GDSC, 22 in CTRP), CYFIP1 (related to 30 cancer drugs in GDSC, 30 in CTRP), and IFIT5 (related to 26 cancer drugs in GDSC, 30 in CTRP), indicating the patients with higher mRNA expression level of these regulator genes might exhibit drug-resistance when treated with these compounds. This evidence concerns the gene NUDT16 and cancer.